Skip to main content

Exelixis Inc(EXEL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low40.55
Day High41.74
Open:41.67
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Exelixis Inc

Select a category then submit the form to load news
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Hims & Hers Health (HIMS) and Regeneron (REGN)
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Intellia Therapeutics (NTLA) and Sarepta Therapeutics (SRPT)
Tipranks
Analysts Are Neutral on Top Healthcare Stocks: Amgen (AMGN), Treace Medical Concepts (TMCI)
Tipranks
RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Exelixis (EXEL) and Sarepta Therapeutics (SRPT)
Motley Fool
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade
Newswire.ca
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
Motley Fool
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
Tipranks
RBC Capital Keeps Their Hold Rating on Exelixis (EXEL)
MarketBeat
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
MarketBeat.com
Tipranks
Exelixis (EXEL) Receives a Buy from Stephens
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Exelixis (EXEL), Edwards Lifesciences (EW) and Zimmer Biomet Holdings (ZBH)
Tipranks
RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL)
Tipranks
Morgan Stanley Keeps Their Hold Rating on Exelixis (EXEL)
Tipranks
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI)
Zacks Investment Research
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
Motley Fool
Exelixis (EXEL) Q4 2025 Earnings Call Transcript
Tipranks
Barclays Sticks to Its Hold Rating for Exelixis (EXEL)
Tipranks
Exelixis (EXEL) Receives a Hold from RBC Capital
Motley Fool
2 Stocks That Could Soar This Year
Tipranks
Analysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Exelixis (EXEL)
Tipranks
Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL)
Tipranks
Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Exelixis (EXEL) and Ultragenyx Pharmaceutical (RARE)
Motley Fool
2 Healthcare Stocks to Buy for 2026 and Beyond
Tipranks
Klaviyo, Wingstop among Stephens Best Ideas for 2026
Tipranks
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL)
GlobeNewswire
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
Tipranks
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA)
Tipranks
Stifel Nicolaus Remains a Hold on Exelixis (EXEL)
Tipranks
Exelixis (EXEL) Receives a Hold from RBC Capital
Motley Fool
2 Under-the-Radar Stocks to Buy Heading Into 2026

Profile

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.